b

biote Corp
NASDAQ:BTMD

Watchlist Manager
biote Corp
NASDAQ:BTMD
Watchlist
Price: 2.78 USD 1.09% Market Closed
Market Cap: 126.9m USD

Relative Value

The Relative Value of one BTMD stock under the Base Case scenario is 8.14 USD. Compared to the current market price of 2.78 USD, biote Corp is Undervalued by 66%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BTMD Relative Value
Base Case
8.14 USD
Undervaluation 66%
Relative Value
Price
b
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
77
vs Industry
69
Median 3Y
1.2
Median 5Y
1.2
Industry
2.6
Forward
0.6
vs History
60
vs Industry
6
Median 3Y
8.9
Median 5Y
9.1
Industry
21.7
Forward
3.8
vs History
60
vs Industry
48
Median 3Y
5.1
Median 5Y
4
Industry
16.7
vs History
vs Industry
5
Median 3Y
-1.4
Median 5Y
-1.2
Industry
23.1
vs History
vs Industry
53
Median 3Y
-3.8
Median 5Y
-4.3
Industry
2.2
vs History
79
vs Industry
57
Median 3Y
1.5
Median 5Y
1.4
Industry
2.9
Forward
1.1
vs History
79
vs Industry
67
Median 3Y
2.1
Median 5Y
2.1
Industry
5.5
vs History
58
vs Industry
35
Median 3Y
7.3
Median 5Y
6.4
Industry
13.2
Forward
3.9
vs History
56
vs Industry
37
Median 3Y
8.1
Median 5Y
7.1
Industry
16.8
Forward
5.8
vs History
60
vs Industry
45
Median 3Y
7.5
Median 5Y
6.4
Industry
15.9
vs History
60
vs Industry
33
Median 3Y
8.2
Median 5Y
7.6
Industry
19.2
vs History
75
vs Industry
18
Median 3Y
4.6
Median 5Y
4.3
Industry
1.9

Multiples Across Competitors

BTMD Competitors Multiples
biote Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
biote Corp
NASDAQ:BTMD
126.9m USD 0.6 4.4 5.8 6.5
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55 36.9 39.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
496.6B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
259.2B CHF 4.2 27.5 11.7 13.7
UK
AstraZeneca PLC
LSE:AZN
212B GBP 4.9 30.2 108.4 158.6
CH
Novartis AG
SIX:NOVN
208.2B CHF 4.7 18.2 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
251.4B USD 3.9 13.2 9.4 11.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.3 9.3 10.8
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
US
b
biote Corp
NASDAQ:BTMD
Average P/E: 21.8
4.4
60%
0.1
US
Eli Lilly and Co
NYSE:LLY
55
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.5
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
CH
Novartis AG
SIX:NOVN
18.2
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
b
biote Corp
NASDAQ:BTMD
Average EV/EBITDA: 399.5
5.8
19%
0.3
US
Eli Lilly and Co
NYSE:LLY
36.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.4
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
b
biote Corp
NASDAQ:BTMD
Average EV/EBIT: 1 710.8
6.5
3%
2.2
US
Eli Lilly and Co
NYSE:LLY
39.6
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.7
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.6
23%
6.9
CH
Novartis AG
SIX:NOVN
14.9
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.2
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
8%
1.3